TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 11/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+4.16%+3.04%+49.37%+94.17% 74.16B
+1.01%-2.49%+21.15%+80.57% 57.39B
+0.81%-2.60%+2.12%+35.51% 47.64B
+0.36%+0.81%+342.39%+748.97% 44.29B
-0.96%-4.50%+24.96%+31.45% 42.5B
-0.20%-0.77%+4.13%+111.69% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+3.75%+31.90%+29.14% 28.53B
+0.05%-1.64%-8.14%-12.10% 24.34B
Average +0.63%-0.59%+53.02%+130.39% 43.39B
Weighted average by Cap. +1.03%-0.84%+57.28%+139.72%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock